| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Large amounts of coproporphyrin III methyl ester have been consistently recovered from urine and feces. Significant elevations in the excretion of coproporphyrin III have not been linked to liver illness, metal or chemical poisoning, or porphyria symptoms [1]. To investigate the processes by which chemicals cause the accumulation of intermediates in the heme production pathway, primary cultures of chicken embryo hepatocytes have been employed. With the porphyrin precursor 5-aminolevulinic acid (ALA), the addition of insulin significantly increases the buildup of uroporphyrin I and Coproporphyrin III. Coproporphyrin III is increased and uroporphyrin I is eliminated by antioxidants[2].
|
|---|---|
| ln Vivo |
Before cancer manifests, urinary DMA and porphyrin levels may serve as early warning indicators of prolonged exposure to MMA. All treatment groups showed a significant rise in Coproporphyrin III concentration levels after 4 weeks as compared to the control group [3].
|
| References |
|
| Additional Infomation |
Coproporphyrin III is a coproporphyrin. It is a human metabolite. It is the conjugate acid of coproporphyrin III(4-). Coproporphyrin III is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain).
|
| Molecular Formula |
C36H40N4O8+2.2[CL-]
|
|---|---|
| Molecular Weight |
727.6308
|
| Exact Mass |
654.268
|
| CAS # |
14643-66-4
|
| Related CAS # |
68938-73-8 (di-hydrochloride)
|
| PubChem CID |
114935
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.366 g/cm3
|
| Boiling Point |
1258ºC at 760 mmHg
|
| Flash Point |
714.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.638
|
| LogP |
4.697
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
48
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XNBNKCLBGTWWSD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H38N4O8/c1-17-21(5-9-33(41)42)29-14-27-19(3)22(6-10-34(43)44)30(39-27)15-28-20(4)24(8-12-36(47)48)32(40-28)16-31-23(7-11-35(45)46)18(2)26(38-31)13-25(17)37-29/h13-16,38,40H,5-12H2,1-4H3,(H,41,42)(H,43,44)(H,45,46)(H,47,48)
|
| Chemical Name |
3-[8,13,18-tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,24-dihydroporphyrin-2-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 83.3 mg/mL (~127.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3743 mL | 6.8716 mL | 13.7432 mL | |
| 5 mM | 0.2749 mL | 1.3743 mL | 2.7486 mL | |
| 10 mM | 0.1374 mL | 0.6872 mL | 1.3743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
